Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVTE Aerovate Therapeutics	$6.76 -2.6%	$33.64	$43.75 ▼ $105.00	$195.94M	0.95	19,273 shs	240,117 shs
IMUX Immunic	$0.82 +1.9%	$0.94	$0.56 ▼ $2.11	$78.62M	1.48	885,362 shs	670,798 shs
LPTX Leap Therapeutics	$0.39 -4.3%	$0.38	$0.22 ▼ $4.79	$16.26M	-0.23	844,307 shs	219,807 shs
MGTA Magenta Therapeutics	$0.70 -7.7%	$0.53	$0.32 ▼ $2.07	$42.44M	2.12	848,835 shs	376,000 shs

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVTE Aerovate Therapeutics	0.00%	-5.98%	-8.65%	-92.15%	-99.22%
IMUX Immunic	0.00%	+2.09%	-16.24%	-29.39%	-32.36%
LPTX Leap Therapeutics	0.00%	+4.30%	+2.22%	-3.51%	-80.57%
MGTA Magenta Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AVTE Aerovate Therapeutics	1.8024 of 5 stars	3.0	0.0	0.0	2.4	1.7	0.6
IMUX Immunic	3.0882 of 5 stars	3.6	3.0	0.0	2.7	2.5	0.6
LPTX Leap Therapeutics	2.7393 of 5 stars	3.1	4.0	0.0	3.3	0.0	1.3
MGTA Magenta Therapeutics	0.8289 of 5 stars	0.0	0.0	4.7	0.6	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVTE Aerovate Therapeutics	2.00	Hold	$78.75	1,064.94% Upside
IMUX Immunic	3.25	Buy	$11.60	1,313.77% Upside
LPTX Leap Therapeutics	2.25	Hold	$4.92	1,153.29% Upside
MGTA Magenta Therapeutics	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest AVTE, MGTA, LPTX, and IMUX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/5/2025	IMUX Immunic	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
5/29/2025	IMUX Immunic	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$17.00 ➝ $10.00
5/23/2025	IMUX Immunic	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00 ➝ $5.00
5/16/2025	IMUX Immunic	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
5/1/2025	IMUX Immunic	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
4/30/2025	IMUX Immunic	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$17.00 ➝ $17.00
4/16/2025	IMUX Immunic	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00 ➝ $6.00
4/15/2025	IMUX Immunic	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
4/10/2025	IMUX Immunic	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$17.00 ➝ $17.00
4/1/2025	IMUX Immunic	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$17.00 ➝ $17.00
3/27/2025	LPTX Leap Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral

(Data available from 6/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVTE Aerovate Therapeutics	N/A	N/A	N/A	N/A	$3.96 per share	N/A
IMUX Immunic	N/A	N/A	N/A	N/A	$0.64 per share	N/A
LPTX Leap Therapeutics	N/A	N/A	N/A	N/A	$2.35 per share	N/A
MGTA Magenta Therapeutics	N/A	N/A	N/A	N/A	$1.23 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVTE Aerovate Therapeutics	-$75.52M	-$1.70	N/A	N/A	N/A	N/A	-90.19%	-77.47%	8/11/2025 (Estimated)
IMUX Immunic	-$93.61M	-$1.23	N/A	N/A	N/A	N/A	-169.55%	-118.96%	8/6/2025 (Estimated)
LPTX Leap Therapeutics	-$81.41M	-$1.70	N/A	N/A	N/A	N/A	-116.24%	-93.18%	8/11/2025 (Estimated)
MGTA Magenta Therapeutics	-$76.46M	N/A	0.00	∞	N/A	N/A	-70.88%	-57.27%	N/A

Latest AVTE, MGTA, LPTX, and IMUX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	IMUX Immunic	-$0.25	-$0.25	N/A	-$0.25	N/A	N/A
5/13/2025	Q1 2025	LPTX Leap Therapeutics	-$0.38	-$0.37	+$0.01	-$0.37	N/A	N/A
4/25/2025	Q4 2024	AVTE Aerovate Therapeutics	-$10.50	-$3.15	+$7.35	-$0.09	N/A	N/A
3/27/2025	Q4 2024	AVTE Aerovate Therapeutics	-$6.65	-$6.65	N/A	-$0.19	N/A	N/A
3/26/2025	Q4 2024	LPTX Leap Therapeutics	-$0.39	-$0.37	+$0.02	-$0.37	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVTE Aerovate Therapeutics	N/A	N/A	N/A	N/A	N/A
IMUX Immunic	N/A	N/A	N/A	N/A	N/A
LPTX Leap Therapeutics	N/A	N/A	N/A	N/A	N/A
MGTA Magenta Therapeutics	N/A	N/A	N/A	N/A	N/A

Latest AVTE, MGTA, LPTX, and IMUX Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
4/9/2025	AVTE Aerovate Therapeutics		$84.00		4/29/2025	4/25/2025	4/28/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVTE Aerovate Therapeutics	N/A	8.78	8.78
IMUX Immunic	N/A	2.71	2.71
LPTX Leap Therapeutics	N/A	3.97	3.97
MGTA Magenta Therapeutics	N/A	19.49	19.49

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVTE Aerovate Therapeutics	N/A
IMUX Immunic	51.82%
LPTX Leap Therapeutics	30.46%
MGTA Magenta Therapeutics	47.53%

Insider Ownership

Company	Insider Ownership
AVTE Aerovate Therapeutics	24.90%
IMUX Immunic	4.60%
LPTX Leap Therapeutics	7.50%
MGTA Magenta Therapeutics	15.18%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVTE Aerovate Therapeutics	20	28.99 million	21.69 million	Optionable
IMUX Immunic	70	95.82 million	87.38 million	Optionable
LPTX Leap Therapeutics	40	41.44 million	36.25 million	Optionable
MGTA Magenta Therapeutics	67	60.67 million	51.46 million	Not Optionable

AVTE, MGTA, LPTX, and IMUX Headlines

Recent News About These Companies

Magenta Skateboards 15-Year Anniversary Show in Paris, June 20-23

June 12, 2025 | msn.com

Third Time's the Charm: Magenta Giving Month Breaks Records With $3.3M in Donations, 27K+ Volunteer Hours

May 19, 2025 | finance.yahoo.com

Montra Electric signs pact with Magenta Mobility for supply of 100 eSCVs

April 23, 2025 | dailyexcelsior.com

Magenta Token Pre-Sale Now Live: Pioneering a New Era in the MagentaVerse Ecosystem

November 15, 2024 | markets.businessinsider.com

Magenta Project: Sam Davies, Pip Hare, and Mariana Lobato share their pathways

November 7, 2024 | sail-world.com

Magenta Mobility’s FY24 revenue rises three fold, losses widen by 17.1%

November 7, 2024 | yourstory.com

Fanfulla - Magenta head to head game preview and prediction

November 5, 2024 | afootballreport.com

Magenta Hotels makes first Northern acquisition

October 28, 2024 | placenorthwest.co.uk

VIRAL | Chattisgarh Man's Desi Recreation Of Magenta Riddim Impresses DJ Snake, Netizens React

October 20, 2024 | republicworld.com

Casatese - Magenta head to head game preview and prediction

October 19, 2024 | afootballreport.com

Oculi Launches Early Access Evaluation Program with Magenta and Burgundy Platforms

October 15, 2024 | 01net.it

Magenta Living and Seddon team up to help apprentices using Widnes-based development

October 11, 2024 | msn.com

Magenta Living and Bolton-based Seddon Housing Partnerships team up to help apprentices

October 9, 2024 | msn.com

Magenta Mobility expands its fleet to over 2,000 EVs

October 4, 2024 | electrive.com

Magenta Associates becomes employee owned

October 1, 2024 | workplaceinsight.net

Magenta Mobility Achieves Major Milestone With Over 2,000 Electric Vehicles In India

September 28, 2024 | drivespark.com

Magenta sharing gas safety advice at pop-ups this week

September 11, 2024 | msn.com

Chhattisgarh DJ’s desi twist to ‘Magenta Riddim’ impresses DJ Snake, viral video stuns the internet

September 2, 2024 | indianexpress.com

Delhi Metro Phase-IV: Safety nod in, Magenta Line extension may open next month

August 30, 2024 | msn.com

Live in Studio B, Wednesday at 11am: Magenta Sunshine

August 26, 2024 | wncw.org

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVTE, MGTA, LPTX, and IMUX Company Descriptions

Aerovate Therapeutics NASDAQ:AVTE

$6.76 -0.18 (-2.59%)

As of 06/13/2025

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Immunic NASDAQ:IMUX

$0.82 +0.02 (+1.94%)

Closing price 04:00 PM Eastern

Extended Trading

$0.83 +0.01 (+0.67%)

As of 07:59 PM Eastern

Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company is also developing IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.

Leap Therapeutics NASDAQ:LPTX

$0.39 -0.02 (-4.29%)

Closing price 04:00 PM Eastern

Extended Trading

$0.41 +0.02 (+4.26%)

As of 07:50 PM Eastern

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, Inc. has an option and license agreement with NovaRock, Adimab, and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.

Magenta Therapeutics NASDAQ:MGTA

Magenta Therapeutics, Inc., a biotechnology company focus on improving stem cell transplantation. Its product candidates are designed to bring the curative power of stem cell transplant to patients with blood cancers, genetic diseases, and autoimmune diseases. The company's product portfolio includes MGTA-117, an anti-CD117 antibody conjugated to an amanitin payload that targets hematopoietic stem cells (HSCs) and leukemia cells; and MGTA-45, an anti-human CD45 antibody conjugated to a DNA-interacting payload for HSCs, leukemia cells, and immune cells. In addition, it focus on development of ADC-based conditioning program that targets a receptor of T cells; and novel conditioning and translation stem cell sciences, as well as develops cell therapy program, E478, which is a small molecule aryl hydrocarbon receptor antagonist for stem cell-based gene therapy and genome editing. In addition, the company has a research and clinical collaboration agreement with AVROBIO, Inc. for the treatment of lysosomal storage disorders; and Beam Therapeutics, Inc. to evaluate the potential utility of MGTA-117 for conditioning of patients with sickle cell disease and beta-thalassemia. Magenta Therapeutics, Inc. was formerly known as HSCTCo Therapeutics, Inc. and changed its name to Magenta Therapeutics, Inc. in February 2016. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time